Category: Cognitive Disorders (non-PD)
Objective: A comparative analysis of the characteristics of cognitive impairment in Parkinson’s disease patients with and without Сovid-19.
Background: Covid-19 infection strongly affects the central nervous system, leading to increased motor and non-motor disturbances in patients with PD.
Method: A total of 124 patients with PD were examined. Patients with PD were divided into 2 groups. Group 1 consisted of 64 patients with PD and Covid-19 infection, and group 2 with PD and no Covid-19 infection. The level of cognitive impairment was analyzed using the Montreal Cognitive Assessment (MoCA) scale
Results: The obtained results show that the average index of this scale was 24.2±2.23 points in the control group of patients with PD in the control group and showed mild cognitive impairment. In group 2 patients this indicator had 22.6±1.89 points, while in group 1 patients it was known that the average score was 18.1±2.43 points. it happened. The difference between group 2 and 3 patients was p≤0.05, and the difference between group 1 and 2, as well as group 1 and 3 patients was p≤0.001.. In group 3 patients, the index of this scale showed 3.6±1.84 points, while in group 2 it showed 3.3±0.88 points, respectively, in the first group of patients it had 2.71±1.03 points, p≤0.001.
Conclusion: The course of cognitive impairment in patients with PD from Covid-19 has a specific character, dementia-like disorders are relatively common and manifest depending on the clinical forms of the disease, as well as the period after infection.
To cite this abstract in AMA style:
R. Matmurodov, B. Muminov, K. Khalimova. The course of cognitive impairment in Parkinson’s disease patients with Сovid-19 [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/the-course-of-cognitive-impairment-in-parkinsons-disease-patients-with-%d1%81ovid-19/. Accessed November 21, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-course-of-cognitive-impairment-in-parkinsons-disease-patients-with-%d1%81ovid-19/